Sartorius Stedim Biotech 将来の成長

Future 基準チェック /46

Sartorius Stedim Biotech利益と収益がそれぞれ年間21%と10.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に17.1% 20.6%なると予測されています。

主要情報

21.0%

収益成長率

20.6%

EPS成長率

Life Sciences 収益成長	0%
収益成長率	10.9%
将来の株主資本利益率	17.1%
アナリストカバレッジ	Good
最終更新日	28 Mar 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:DIM N - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,915	567	407	1,130	4
12/31/2025	3,441	497	417	954	9
12/31/2024	3,004	359	367	896	10
12/31/2023	2,776	310	273	746	N/A
9/30/2023	2,959	460	113	625	N/A
6/30/2023	3,170	635	162	675	N/A
3/31/2023	3,356	717	137	606	N/A
12/31/2022	3,493	876	182	612	N/A
9/30/2022	3,381	681	125	552	N/A
6/30/2022	3,259	625	193	584	N/A
3/31/2022	3,094	559	322	661	N/A
12/31/2021	2,887	414	378	702	N/A
9/30/2021	2,639	523	355	623	N/A
6/30/2021	2,393	469	367	590	N/A
3/31/2021	2,143	398	310	506	N/A
12/31/2020	1,910	336	258	417	N/A
9/30/2020	1,743	299	299	414	N/A
6/30/2020	1,600	255	243	365	N/A
3/31/2020	1,520	254	216	345	N/A
12/31/2019	1,441	235	174	310	N/A
9/30/2019	1,393	247	142	291	N/A
6/30/2019	1,336	238	21	261	N/A
3/31/2019	1,274	223	88	270	N/A
12/31/2018	1,212	208	51	227	N/A
9/30/2018	1,172	185	57	226	N/A
6/30/2018	1,121	173	147	225	N/A
3/31/2018	1,093	162	66	196	N/A
12/31/2017	1,081	161	48	175	N/A
9/30/2017	1,073	151	N/A	165	N/A
6/30/2017	1,089	157	N/A	169	N/A
3/31/2017	1,075	157	N/A	146	N/A
12/31/2016	1,052	154	N/A	157	N/A
9/30/2016	1,009	145	N/A	146	N/A
6/30/2016	971	142	N/A	129	N/A
3/31/2016	926	136	N/A	155	N/A
12/31/2015	884	118	N/A	143	N/A
9/30/2015	850	111	N/A	150	N/A
6/30/2015	781	89	N/A	128	N/A
3/31/2015	734	76	N/A	113	N/A
12/31/2014	684	72	N/A	111	N/A
9/30/2014	646	71	N/A	93	N/A
6/30/2014	620	67	N/A	110	N/A
3/31/2014	604	68	N/A	97	N/A
12/31/2013	588	66	N/A	90	N/A
9/30/2013	567	63	N/A	70	N/A
6/30/2013	564	65	N/A	62	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DIM Nの予測収益成長率 (年間21% ) は貯蓄率 ( 7.7% ) を上回っています。

収益対市場: DIM Nの収益 ( 21% ) はMX市場 ( 11.3% ) よりも速いペースで成長すると予測されています。

高成長収益: DIM Nの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: DIM Nの収益 ( 10.9% ) MX市場 ( 7.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: DIM Nの収益 ( 10.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DIM Nの自己資本利益率は、3年後には低くなると予測されています ( 17.1 %)。

Sartorius Stedim Biotech 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Recent updates

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.

Insufficient new directors

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

Less than half of directors are independent

Less than half of directors are independent

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Less than half of directors are independent

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘